Cellin Technologies is a cell therapy products contract manufacturing company developing proprietary technologies to produce cells for experimental or clinical applications. Cellin Technologies provides services to biopharma and biotech companies, both in Estonia and external markets.
Cellin Technologies – cell therapy products
Cellin Technologies uses different disease models to optimize therapeutic effects of stem cells. Cellin is focused on molecular mechanisms of stem cell proliferation and differentiation with a main emphasis on development of techniques to manipulate homing, differentiation and integration of cells following transplantation. Cellin Technologies has a partnership for a EU-funded Research and Development project studying how to use regenerative cells from human fat for the creation of new blood vessels. This unique platform technology employs human adult mesenchymal stem cells from adipose tissue to produce cell products of the highest quality.
Furthermore, Cellin Technologies recently started the production of melanoma cell lysate, the critical raw material required for manufacturing MelCancerVac (a colorectal cancer vaccine developed by DanDrit Biotech). Therapeutic dendritic cell-based vaccination of cancer patients represents one of the most promising non-toxic methods of cancer treatment. DanDrit Biotech uses the patient’s own dendritic cells and loads them with tumor antigens from the lysate of a specifically selected melanoma cell line. The ability of these dendritic cells to induce a strong immune response is the basis of MelCancerVac vaccine. MelCancerVac has been tested in clinical trials for the treatment of colorectal cancer (CRC) and non-small-cell lung cancer (NSCLC). Phase I and phase II trials were carried out with success. Phase IIb/III trials will be carried out using the vaccine manufactured by Cellin Technologies. Cellin Technologies has a contract to manufacture the vaccine for 174 patients participating in Phase III of the clinical trials, and up to 500 patients taking part in a patient name use program. Cellin Technologies uses a state-of-the-art GMP cleanroom facility for the production of medicinal cell therapy products.
Cellin Technologies LLC is a biotech company founded in 2008 and located in Tallinn Science Park Tehnopol (Estonia). Management Team is composed by Toomas Neuman (CSO), Kairit Tints, Reet Rumvolt, Piia Kivipõld, Jüri Laasik, Ivar Järving and Mart Raik (CEO). Cellin Technologies uses two cleanroom suites classified as Grade B and Grade A according to EU GMP for the manufacturing of cell products. Each cleanroom is equipped in compliance with highest technological and quality standards. The availability of two separate cleanrooms enables simultaneous handling of different cell products without risk of cross-contamination.
More about Cellin Technologies : www.cellintechnologies.com